Perseid meteor shower
This shower peaks in mid-August, when Earth intersects the dust cloud left by comet Swift-Tuttle.
Pooja hesitated. Then she opened a drawer. Inside were forty sheets of blank prescription pads—with Dr. Iyengar’s forged stamp.
Outside, the city was asleep. But somewhere, a patient with chronic bronchitis was breathing shallowly, having bought only half a course of the expectorant, leaving the steroid untouched—because a chemist had whispered, “Don’t take this combo, beta. Too risky.”
“Primary sales are strong,” his boss had said in the morning review. “But secondary is dead. The product is leaving our warehouse but not moving off pharmacy shelves.” Fdc Sales Mis
Or so they believed.
“Yes sir, forty scripts. I saw them myself. She wrote them in front of me.” Pooja hesitated
“Arjun bhai, your Nebuflam-D is moving slow because the retailers are scared. Two months ago, the state drug controller banned another FDC—same steroid, different company. The wholesalers are still stuck with thirty lakhs of expired stock. So now, every time a retailer sees ‘low-dose steroid’ on a combo, they think: next ban . They order just one strip at a time. And the patient? If the doctor writes a combo, the patient asks the chemist, ‘Can I take just the expectorant alone?’ Then they buy half a course.”
Palpitations. The steroid component had a known but rare cardiac risk. In clinical trials, it occurred in 0.3% of patients. But if even one patient reported it to a senior doctor like Iyengar, she would blacklist the FDC forever. The MIS, however, would not capture why she stopped. It would only show a line descending. Numbers without stories were dangerous. Iyengar’s forged stamp
Someone was entering fake prescriptions into the system to game the CRM.
“Rajesh gave me these,” she whispered. “He said, ‘Just enter them. The system will never know. The expiry dates are old anyway.’”
But who? A rep desperate to meet target? A stockist colluding with a retailer? Or the MIS itself—not the software, but the people who controlled what data entered it.
The drug was called Nebuflam-D . A fixed-dose combination of an expectorant, a low-dose steroid, and a novel mucolytic. It was supposed to be a blockbuster for chronic bronchitis. The clinical trials were solid. The pricing was aggressive. The sales force was incentivized to the teeth.
